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Résumé 
Dues à leur importance croissante dans la dégénérescence musculaire, les 
mitochondries sont de plus en plus étudiées en relation à diverses myopathies.   Leurs 
mécanismes de contrôle de qualité sont reconnus pour leur rôle important dans la 
santé mitochondrial.  Dans cette étude, nous tentons de déterminer si le déficit de 
mitophagie chez les souris déficiente du gène Parkin causera une exacerbation des 
dysfonctions mitochondriales normalement induite par la doxorubicine.  Nous avons 
analysé l’impact de l’ablation de Parkin en réponse à un traitement à la doxorubicine 
au niveau du fonctionnement cardiaque, des fonctions mitochondriales et de 
l’enzymologie mitochondriale.  Nos résultats démontrent qu’à l’état basal, l’absence 
de Parkin n’induit pas de pathologie cardiaque mais est associé à des dysfonctions 
mitochondriales multiples.  La doxorubicine induit des dysfonctions respiratoires, du 
stress oxydant mitochondrial et une susceptibilité à l’ouverture du pore de transition 
de perméabilité (PTP).  Finalement, contrairement à notre hypothèse, l’absence de 
Parkin n’accentue pas les dysfonctions mitochondriales induites par la doxorubicine 
et semble même exercer un effet protecteur. 
 
Mots clés : mitochondrie, respiration, ROS, mPTP, muscle cardiaque, autophagie, 
parkin, mitophagie, doxorubicine. 
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Summary 
Mitochondria are becoming the focus of many studies because of their increasingly 
important role in cellular damage and related myopathies.  Their endogenous quality 
control mechanisms are recognized for their crucial role in mitochondrial health.  In 
our study, we attempted to determine if the deficit of mitophagy in Parkin deficient 
mice would cause an exacerbation of mitochondrial dysfunctions usually induced by 
doxorubicin.  We have analyzed the impact of the ablation of Parkin in response to 
treatment with doxorubicin at the level of cardiac functions, mitochondrial functions 
as well as mitochondrial enzymology.  Our results demonstrated that at baseline, the 
absence of Parkin didn’t induce cardiac pathologies but was associated with many 
mitochondrial dysfunctions.  Doxorubicin induced respiratory dysfunctions, 
mitochondrial oxidative stress as well as greater susceptibility to permeability 
transition pore (PTP) opening.  Finally, contrary to our hypothesis, the absence of 
Parkin, didn’t exacerbate mitochondrial dysfunctions induced by doxorubicin and 
seemed to have a protective effect.   
 
Key words: mitochondria, respiration, ROS, mPTP, cardiac muscle, autophagy, 
parkin, mitophagy, doxorubicin.    
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Foreword 
 
This memoir was done under the supervision of Dr. Yan Burelle who runs a 
laboratory focused on mitochondrial dysfunctions and their implications in different 
pathologies.  His laboratory has the appropriate equipment to study mitochondrial 
respiration, reactive oxygen species production, calcium regulation through the 
permeability transition pore, cell death signaling and other mitochondria related 
events.  This memoir appropriately depicts mitochondrial dysfunctions related to 
doxorubicin-induced cardiotoxicity. 
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1.1 Introduction: 
 
Mitochondria are specialized organelles originating from the symbiotic 
engulfment of aerobic-proteobacteria by pre-eukaryotic cells more than 1.5 billion 
years ago. Over the course of evolution, mitochondria have evolved as specialized 
organelles with a plethora of cellular functions. They play a central role in adenosine 
triphosphate (ATP) production through oxidative phosphorylation (OXPHOS). They 
actively participate in cellular Ca2+ dynamics by their capacity to take up and release 
Ca2+(Bernardi 2013). They generate metabolic outputs, which can modulate multiple 
signalling cascades, and nuclear gene expression programs through genetic and 
epigenetic mechanisms. They constitute one of the main sources of reactive oxygen 
species (ROS), which can participate in cell signalling or cell dysfunction/death under 
physiological and pathological conditions respectively (Inoue, Sato et al. 2003). 
Finally, in response to stress-induced signalling events converging to mitochondria, 
or of intrinsic dysfunctions within mitochondria caused by acute or chronic 
pathological conditions, these organelles can trigger apoptotic and necrotic cell death 
through permeabilization of their double membrane system (Bernardi 2013).  
 
Considering the vital importance of mitochondria in cellular homeostasis, 
sophisticated mechanisms have evolved to prevent the accumulation of 
mitochondrial functional abnormalities through the continuous turnover of 
organelles. This process involves the replacement of mitochondrial biomass through 
mitochondrial biogenesis, and the balanced degradation of dysfunctional or damaged 
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organelles through various quality control (QC) mechanisms, which remain poorly 
understood (Kissova, Deffieu et al. 2004).  
 
In the heart, where mitochondria account for 30-35% of cardiomyocyte 
volume, abnormalities in one or several facets of mitochondrial function have been 
involved in a wide variety of cardiac diseases including ischemia-reperfusion injury, 
overload-induced ventricular remodelling, chronic heart failure, genetic 
cardiopathies, as well as cardiopathies associated with sepsis or anthracyclin-based 
chemotherapy (Ballinger 2005). However, despite this knowledge, little is known 
about the role of mitochondrial QC in disease development in the heart, and the 
relationship between mitochondrial QC and the appearance of mitochondrial 
dysfunction. 
 
Recently, our laboratory and others have focused on mitophagy, a QC process 
whereby mitochondria destined for elimination are sequestered in double membrane 
autophagosomes, and delivered to lysosomes for subsequent degradation (Kissova, 
Deffieu et al. 2004). Indeed, while this process is emerging as central for proper 
cellular homeostasis, its role in the heart remains unclear. More specifically, the role 
of mitophagy in the development of cardiopathies, and the appearance of 
mitochondrial dysfunction during disease remains largely unknown.  
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For this reason, the purpose of this M.Sc. thesis was to determine the potential 
impact of genetically impairing mitophagy on the development of stress-induced 
mitochondrial and cardiac dysfunction. For this purpose, we chose to use 
doxorubicin-induced cardiotoxicity as a model due to the well-established impact of 
doxorubicin on mitochondrial functions and structure, and the clinical relevance of 
this model.  
 
Considering the nature of the experimental work, the literature review 
presented below provides an overview of mitochondrial structure and function, with 
a discussion on the impact of doxorubicin on various facets of mitochondrial biology 
in the heart.  This is followed by the presentation of essential concepts that pertain to 
mitochondrial QC, particularly mitophagy, and how these processes may be impacted 
in the context of doxorubicin-induced mitochondrial and cardiac toxicity. 
 
 
 
1.2 The essential of mitochondrial biology: Morphology and functions 
1.2.1  Mitochondrial Morphology: 
 
Mitochondria, similar to their bacterial ancestors are composed of two 
membranes, the outer (MOM) and inner (MIM) membranes, which delineate 3 
distinct compartments, the cytoplasm, the inter-membrane space (IMS) and the 
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mitochondrial matrix (1). The MOM, which is characterized by a smooth appearance 
when imaged by electron microscopy, separates the organelle from the cytosolic 
compartment. It is composed of 50% lipids and 50% proteins, some being integral 
and harbouring trans-membrane domains, and others being peripheral. These 
proteins are involved in various functions including fatty acid and protein import into 
mitochondria, exchange of hydrophilic solutes, and creation of docking sites to enable 
interactions between mitochondria and other organelles(Linden, Nelson et al. 1989).  
 
The MIM, which is characterized by a rough appearance when imaged by 
electron microscopy, has a much higher protein density. It also has a much larger 
surface area then the MOM, which allows the formation of multiple folds or 
invaginations called cristae. These cristae form a microenvironment where electron 
transport complexes and mobile electron carriers forming the respiratory chain are 
preferentially concentrated to improve their catalytic efficiency (Frey and Mannella 
2000).  The MIM is in general very impermeable to proteins, metabolites, and solutes. 
Transport across the membrane is therefore mediated by a wide variety of specific 
membrane-spanning carrier proteins including the translocase of the inner 
membrane (TOM) complex, the adenine nucleotide exchanger (ANT), numerous ion 
and di- or tri-carboxylate carriers, electron transport chain (ETC) complexes, and the 
ATP synthase. 
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Finally, the matrix is the innermost compartment where a large variety of 
biological processes take place. The matrix contains among other components, 
mitochondrial DNA, which encodes the RNA’s required for the synthesis of some ETC 
complex subunits, and a wide range of enzymes including those of the Krebs cycle and 
β-oxidation, which are essential for biosynthetic processes and energy metabolism. 
 
 As shown in Figure 1 mitochondria has typically been represented as a bean-
shaped organelle. However, it is now commonly accepted that mitochondrial 
morphology can vary extensively, ranging from this classical bean-shaped 
appearance to elongated and highly branched network-like configurations. Moreover, 
experimental evidence revealed that mitochondrial morphology is i) dynamic, ii) 
tightly regulated by specific sets of proteins including Mitofusins (MFN1, MFN2), 
Optic-atrophy factor-1 (OPA1), and Dynamin-Related Protein-1 (DRP1), and iii) 
intimately linked to mitochondrial QC, and key mitochondrial functions such as 
respiration, ROS production, and signalling of cell death (Inoue, Sato et al. 2003) 
(Bernardi 2013). 
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Figure 1: Mitochondrial Structure 
 
 
 
Figure 1: Mitochondrial Structure 
MOM: mitochondrial outer-membrane 
IMS: intermembrane space 
MIM: mitochondrial inner-membrane 
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1.2.2 Mitochondrial OXPHOS 
 
Mitochondria are central hubs of cellular bioenergetics capable of converting 
redox energy contained in the C-H bonds of nutrients, into phosphate energy 
contained in ATP (2). To achieve this function, mitochondria rely not only on its own 
array of metabolic processes (e.g. the Krebs cycle, β-oxidation, and oxidative 
phosphorylation (OXPHOS) machinery) but also on interactions with other pathways 
(ex: glycolysis), or organelles (ex: peroxisomes) involved in intermediary 
metabolism, which provide them with key substrates such as pyruvate and fatty acids, 
and with reducing equivalents (e.g. NADH and FADH2) that can directly fuel OXPHOS 
for ATP synthesis (2). 
 
     The process of OXPHOS relies on the electron transport chain, a series of four 
multi-units metal-containing complexes (CI, CII, CIII, CIV), and two mobile electron 
carriers (coenzyme Q and cytochrome c) present in or on the MIM particularly in 
cristae (2). Together, these proteins are involved in a series of oxido-reduction 
reactions whereby chemical energy contained in NADH and FADH2 is converted into 
a proton electrochemical gradient (ΔμH+) across the MIM, which can in turn be used 
to drive energy consuming processes such as ATP synthesis (2).  
 
More specifically, NADH feeds its electrons at the level of NADH-CoQ 
dehydrogenase (CI), where electrons are transferred to Coenzyme Q (CoQ) through a 
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series of oxido-reduction steps involving flavine mononucleotide (FMN) and several 
iron-sulphur clusters. Reduced CoQ (QH2), a lipid mobile carrier than shuttles the 
electrons to CoQ-cytochrome c reductase (CIII), where they are transferred to the 
mobile electron carrier cytochrome c through a succession of reaction involving heme 
and iron-sulfur clusters containing subunits. Reduced cytochrome c ultimately 
shuttles these electrons to cytochrome c oxidase (CIV), where they are transferred to 
molecular oxygen through a series of steps involving iron and copper containing 
subunits, thus allowing the formation of H2O. During this process, these redox 
reactions allow CI, CIII and CIV to pump protons across the MIM (12H+: 4H+ per 
complex per mole of NADH) to generate the proton electro-chemical gradient (2). 
 
As for FADH2, the other electron shuttle of importance, it feeds its electrons at 
the level of succinate dehydrogenase (SDH or CII), which transfers them to the 
ubiquinone pool directly. In doing so, this electron pathway bypasses CI, thereby 
reducing the bioenergetics efficiency of FADH2 (8H+/mole of FADH2) compared to 
NADH (10H+/mole of NADH). Physiologically, the FADH2 and NADH electron 
pathways function in parallel, although the proportion of NADH vs FADH2 may vary 
depending on the mixture of energy substrate oxidized (2). 
 
Like most metabolic process, the levels of substrates and end-products exert a 
thermodynamic control on the overall reaction rate of the ETC. This means that the 
electron flow, and thus oxygen consumption is regulated by the NADH/NAD+ 
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FADH2/FAD+ (e.g. the substrates) ratios on the one hand, and ΔμH+ (the product) on 
the other hand. Processes that consume ΔμH+, or stimulate the production of NADH 
and FADH2 will increase flux through the ETC, while high ΔμH+ and more oxidized 
NADH/NAD+ and FADH2/FAD+ ratios will lower ETC flux (2).  
 
ATP synthesis is one of the main processes that consume ΔμH+. This is 
achieved by the FoF1-ATPase located in the MIM, which couples the re-entry of 
protons into the mitochondrial matrix to the synthesis of ATP from ADP and Pi. In 
addition, a number of other processes tend to dissipate ΔμH+, and thus stimulate 
respiration including: i) passive or facilitated diffusion of H+ directly through the MIM, 
or through uncoupling proteins (UCP’s), ii) electrogenic transport of several ions and 
metabolites and iii) physiological or pathological slippage of proton pumps along the 
ETC. In vivo, mitochondrial respiration rates will therefore vary considerably 
depending on ATP demand, but will also be modulated by the various energy 
consuming or dissipating processes (2). 
 
   From a physiopathological standpoint, a number of factors can negatively impact 
the capacity of mitochondria to generate ATP. This includes shortage of metabolic 
substrate and/or O2, dissipation of ΔμH+ independent of ATP synthesis, inhibition of 
and/or physical damage to one or several complexes involved in OXPHOS, and 
damage to mtDNA that impair the capacity to synthetize new ETC complexes. As 
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reviewed below, doxorubicin directly impacts myocardial OXPHOS through several 
of these mechanisms (2). 
Figure 2: The Electron Transport Chain 
 
 
Figure 2: The Electron Transport Chain 
By pumping protons into the IMS, the ETC creates an electrochemical gradient across the IMM or 
MIM enabling re-entering of protons through the complex V and synthesis of ATP.    
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1.2.3 Reactive oxygen species 
In addition to ATP production, mitochondria are also known as important 
sources of cellular reactive oxygen species (ROS). In general, free radicals are species 
containing one or more unpaired electrons, conferring them an important degree of 
reactivity. Oxygen being itself a free radical, it is a favoured recipient of unpaired 
electrons. Thus, the superoxide anion (O2-x) is almost always the first step in the 
formation of free radicals and is accordingly referred to as the primary reactive 
oxygen species (ROS) (Inoue, Sato et al. 2003). O2-x either interacts with nitric oxide 
based molecules to form reactive nitrogen species (RNS), such as peroxynitrite 
(ONOO-x), or, is dismutated into the more stable non-radical ROS, hydrogen peroxide 
(H2O2), by superoxide dismutases (SOD). Finally, hydrogen peroxide can lead to the 
formation of potentially damaging secondary ROS, through enzyme- or metal-
catalyzed reactions (Valko, Leibfritz et al. 2007) (3).  
Although several sources of O2-x exist in cells, mitochondria, which harbor in 
their ETC a complex succession of oxido-reduction reactions, constitute one of the 
major production sites.  Complexes I and III of the ETC are known as the principle 
contributors to mitochondrial O2-x production.  Historically, complex III in particular 
was suggested as the main source of superoxide particularly under conditions of high 
redox states (i.e. inhibition of complex III downstream of the Q cycle), which promote 
the accumulation of ubisemiquinone, the reactive intermediate of the Q cycle 
(Turrens 2003). Ubisemiquinone then reacts with molecular oxygen to generate O2-x 
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primarily in the mitochondrial matrix but also in the inter-membrane space (St-
Pierre, Buckingham et al. 2002) (Han, Williams et al. 2001) (3). 
However, it is increasingly recognized that complex I may actually be the main 
physiological source of O2-x in the ETC.  Complex I generates superoxide at the level 
of the flavin mononucleotide centers (FMN) under conditions of forward electron 
when the complex  I is fed with NADH. This is particularly evident when complex I is 
inhibited downstream of FMN centers by rotenone, which will increase the reduction 
state of FMN centers and promote electron leaks. In  addition, complex I can also 
generate large amounts of O2-x when the ETC is fed with substrates for complex II (i.e. 
with FADH2 donors). In this condition, FADH2 allows to reverse electron flow through 
complex I, which causes a large increase in O2-x at the level of the ubiquinone binding 
site (Q site).  This phenonemon is exacerbated under conditions where forward and 
reverse electron flow are promoted by the simultaneous presence of NADH and 
FADH2 donors to the ETC, which causes an important reduction of complex I. ROS 
production in vivo is therefore likely to be very sensitive to changes in redox state 
and to the absolute electron flux through the ETC (Turrens 2003, Brand 2010) (3). 
Being a primary site of potentially damageable O2-x, mitochondria are 
endowed with a complex array of enzymatic and non-enzymatic antioxidant systems. 
Manganese-dependent superoxide dismutase (Mg-SOD or SOD2) is abundently 
expressed in the mitochondrial matrix where it is responsible for the rapid 
dismutation of O2-x into H2O2., while Zinc-dependent SOD (Zn-SOD or SOD1), is 
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responsible for the dismutation of  O2-x in the intermembrane space and cytosol. A 
number of enzymatic systems exist to eliminate H2O2 within mitochondria including 
i) the glutathione system catalyzed by glutathione peroxidase and reductase, ii) 
catalase,  and iii) the peroxiredoxins system. In addition to these enzymatic systems, 
non-enzymatic antioxidants such as tocopherol (Vitamin E), retinoids (Vitamin A) or 
ascorbates (Vitamin C) also confer some degree of protection against oxidative stress 
(Inoue, Sato et al. 2003) (Cadenas and Davies 2000) (3). 
When the balance between oxidants and antioxidants is lost, there is excess in 
ROS production and subsequent creation of oxidative stress.  This can lead to 
mitochondrial DNA damage as the hydroxyl radical (OH.) reacts with both the purine 
and pyrimidine bases of DNA.  By doing so, it permanently damages the genetic 
material of the cell by modifying its composition.  Oxidative stress can also cause 
peroxidation of membrane phospholipids. The third common side effect of excess 
ROS is protein damage.  The proposed mechanism of action is the formation of a 
carbon-centered radical from reacting with a hydroxyl radical.  The carbon-centered 
complex creates a peroxyl radical by reacting with oxygen to finally react with a 
protonated superoxide forming alkyl peroxide. These reactions can ultimately cause 
peptide bond cleavage. (Valko, Rhodes et al. 2006).                   
Although ROS/RNS can cause harm, their presence to a certain extent is 
required for normal physiological function. In fact, physiological ROS production, by 
activating transcription factors such as MAP-Kinase/AP-1 and NF-kB pathways, is 
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necessary for intracellular signaling, regulation, proliferation and apoptosis. 
Preservation of this delicate equilibrium is thus crucial to maintain normal cellular 
responsivity and avoid adverse effects of oxidative stress on nucleic acids, membrane 
lipids, and proteins (Devasagayam, Tilak et al. 2004). 
In terms of doxorubicin-induced cardiac dysfunction, we will review later that 
generation of excess O2-x at the level of the ETC is a central mechanism driving 
mitochondrial damage and ultimately cardiomyocyte abnormalities. 
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Figure 3: Mitochondrial ROS production and Scavenging 
 
 
Figure 3: Mitochondrial ROS production and Scavenging 
In the cytosol, CuZnSOD detoxifies superoxide anions produced at the complexes I and III of the 
electron transport chain into hydrogen peroxide before being transformed into water by glutathione 
peroxidase.  Inside the matrix, MnSOD detoxifies the superoxide anions produced by both 
complexes I and III before peroxiredoxin detoxifies the peroxide into water.  
SOD: Superoxide dismutase. Gpx: glutathione peroxidase. Prx: Peroxiredoxin. GR: Glutathione 
Reductase. GSH/GSSG reduced/oxidized glutathione.        
 
 
 
 
 
 
 
1.2.4 Mitochondrial membrane permeation and cell death signalling 
Mitochondria also play a key role in the regulation of cell death by their 
capacity to trigger necrosis and apoptosis through permeation of their membranes. 
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Membrane permeation can result from the activation of multiple signaling pathways 
that converge to mitochondria, or from intrinsic dysfunction within mitochondria 
caused by acute or chronic pathological conditions (Kroemer, Galluzzi et al. 2007) .  
 
There is emerging evidence that there is an important distinction to be made 
between outer and inner membrane permeabilization, with each having different 
modes of regulation and different physiological implications (Kroemer, 2007, Phys 
Rev). Although the molecular underpinnings differentiating the two remain unclear, 
the consensus so far establishes that outer membrane permeabilization is performed 
by the insertion of Bcl-2 family BH-3 oligomers into the outer membrane, while inner 
membrane permeabilization is achieved through opening of the mitochondrial 
permeability transition pore (mPTP), which, as described later, is believed to be 
involved in doxorubicin-induced mitochondrial dysfunction (Chacon and Acosta 
1991).  
 
1.2.4.1 The permeability transition pore 
 
Mitochondrial permeability transition was initially described on isolated 
mitochondria as a sudden increase in membrane permeability to solutes in presence 
of high Ca2+ levels. While this phenomenon was believed to be caused by non-specific 
membrane damage, it is not widely recognized to be mediated by the mPTP, a high 
conductance non-specific channel of the inner membrane, which according to the 
   
18 
latest model, is formed by ATP synthase dimers at the crest of mitochondrial cristaes 
(Bernardi 2013). Prolonged and irreversible opening of this pore allows the 
equilibration of solutes of < 1500 Da across the mitochondrial membrane, which has 
several consequences including i) loss of membrane potential, ii) ATP hydrolysis 
through reversal of the ATP synthase, iii) swelling of the mitochodnrial matrix, and 
ultimately rupture of the outer mitochondrial membrane, and iv) release of several 
apoptotic factors including cytochrome c, AIF, SMAC/DIABLO and Endonuclease G 
(Du, Wang et al. 2004).  
 
Regulation of the mPTP is complex and implies a number of modulators. 
Accumulation of Ca2+ in the matrix is the single most important inducer of mPTP 
opening (Choo, Johnson et al. 2004). However, several factors facilitate pore opening 
by increasing its sensitivity to Ca2+ accumulation of inorganic phosphate, reduced 
membrane potential, depletion of ATP and ADP, and oxidative stress being some of 
the most important ones (Brenner and Moulin 2012). In contrast, divalent cations 
such as Mg2+ and adenylates which all bind to the ATP synthase, act as partial 
inhibitors (Beutner, Ruck et al. 1998). 
 
In addition to these regulators, cyclophilin-D (Cyp-D), a member of the 
immunophilin family protein located exclusively in the mitochondrial matrix 
constitutes an important endogenous sensitizer of the mPTP (Baines, Kaiser et al. 
2005). In response to Ca2+ overload or oxidative stress, CypD which is soluble in the 
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matrix is recruited from the inner membrane where it binds the lateral stalk of ATP 
synthase dimers, thus promoting its conversion into the mPTP configuration 
(Bernardi 2013). Cyclosporin-A, the prototypical partial inhibitor of mPTP opening 
was shown to bind Cyp-D specifically thus preventing its membrane recruitment 
under conditions of mitochondrial stress (Bernardi, Krauskopf et al. 2006). 
 
Although the molecular identity of the mPTP has remained elusive for a long 
time, recent studies by the group of Bernardi have provided strong evidence that it is 
in fact formed by ATPsynthase dimers located at the crest on mitochondrial cristae 
(Bernardi 2013). This model is currently the only one able to account for all the 
functional and regulatory features of the mPTP that were previously established 
(Bernardi 2013). 
 
1.3 Mitochondrial quality control 
Maintenance of an optimally functioning mitochondrial pool is absolutely 
essential for cellular homeostasis, particularly in the heart, in which these organelles 
occupy more than 30 % of cellular volume. Over the recent years, it has become clear 
that this essential function is achieved through the action of several quality control 
mechanisms that collectively insure mitochondrial repair, and/or clearance of 
damaged molecular components or entire organelles. In particular, general 
autophagy, and the more specific form of autophagy termed mitophagy have emerged 
as important determinants of mitochondrial health, particularly in cells that are 
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terminally differentiated and are rich in mitochondria such as cardiomyocytes 
(Gottlieb, Finley et al. 2009). 
 
In this section, I will begin by depicting a general overview of autophagy and 
its mechanisms.  I will follow this up with a description of a more selective but still 
misunderstood autophagic process called mitophagy. .       
 
1.3.1 Autophagy: Mechanisms and Pathways 
 
Autophagy consists of a very important and complex cellular process that 
enables cells to maintain their energy levels in situations of starvation and rid 
themselves of protein aggregates and damaged organelles.  Many molecular 
pathways allow autophagy to work its course in response to many different situations 
such as starvation, infections, and damage induced by stress and cellular alterations.  
There are different subgroups of autophagy depending on the organelles or proteins 
targeted for degradation.  In fact, there is macro-autophagy and micro-autophagy 
described by De Duve and Wattiaux as well as chaperones mediated autophagy 
explained by Dice(De Duve and Wattiaux 1966) (Chiang, Terlecky et al. 1989) .  In this 
section of the literature review, we will focus on macro-autophagy (autophagy).   
 
 Regulated by the insulin pathway, starvation is an extensively researched 
method of promoting autophagy.  Conversely, a high caloric diet can inhibit 
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autophagy, thus playing a role in obesity.  Type II diabetes, sedentary lifestyles, and 
metabolic syndromes are also characterized as having reduced levels of autophagy 
(Donati 2006) (Etgen, Oldham et al. 2002).  An experiment in which a common 
autophagic regulator, p62 was knocked out resulted in insulin resistant obese mice 
proving the clear relationship between autophagy and metabolism (Rodriguez, Duran 
et al. 2006).  There are many other examples of the protective virtue of autophagy.  
Amongst these, in an acutely induced stressful environment such as ischemia-
reperfusion, murine myocytes have been found to have a highly autophagic response 
(Gustafsson and Gottlieb 2008).  Exercise has been known to be cardioprotective for 
quite some time, but is now also confirmed to be correlated with a high autophagic 
response (Dohm, Tapscott et al. 1987).  Autophagy has also been shown to be related 
to ageing since many autophagic genes such as Atg2, Atg8a, Atg18, and bchs exhibit 
decline in expression with times allowing for subsequent higher expression of 
dysfunctional protein aggregates (Simonsen, Cumming et al. 2008).   
 
To paint a big picture, the autophagic cargo is engulfed by a double-membrane 
structure built from nearby organelle membranes (autophagosome) and fuses with 
lysosomes for degradation purposes enabled by many lysosomial enzymes.  Work in 
yeast resulted in the discovery of 35 Autophagy Related Genes (Atgs), which are 
highly conserved proteins that play important roles in the molecular pathways of 
autophagy (Takeshige, Baba et al. 1992) (Tsukada and Ohsumi 1993) (4).  There are 
4 main steps in the autophagic process.  The first step consists of the initiation of the 
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formation of phagophore assembly site (PAS: Phagophore Assembly Site).  The 
second step is the elongation and closing of the autophagosome.  The third step is the 
maturation of the autophagosome by fusing with the lysosome.  Finally, the fourth 
step consists of the degradation and recycling of the autophagic cargo by lysosomial 
enzymes.  Throughout these 4 steps, complex signalization and regulatory stimuli act 
at different levels (4).   
 
 
The initiation of the formation of PAS is crucial since it establishes what 
cellular organelle is to be degraded.  Ubiquitine ligase enables ubiquitination of 
proteins.  This allows the recruitement of P62-SQSTM1, which interacts with the 
ubiquitin and allows the damaged proteins destined for degradation to link to an 
LC3 protein (homologue to ATG8), which is found at the surface of PAS (Pankiv, 
Clausen et al. 2007) (Itakura and Mizushima 2011) (Kabeya, Mizushima et al. 2000). 
     
Once the damaged organelle is recognized, membrane precursors initiate the 
formation of the double membrane of the autophagosome near the damaged material 
destined for degradation.  Autophagosomes can originate from different sources such 
as the endoplasmic reticulum, the Golgi apparatus, the endosomes, the plasmic 
membrane and even the mitochondrial membranes (Hayashi-Nishino, Fujita et al. 
2009). 
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In mitochondria, formation of the autophagosomes has been found to be 
dependent on mitofusine 2 (MFN2), which is a protein that also plays an important 
role in fusion and fission of the mitochondrial network.  This points to a clear 
relationship between regulation of autophagy and mitochondrial morphology 
remodeling (Zhao, Huang et al. 2012).   
 
In addition to the linking of the damaged organelles to the autophasome, the 
formation, elongation and closing of the later requires the assembly of a series of 
proteins (Atgs) at the PAS.  These Atgs belong to two conjugation systems: Atg5,12,10 
and Atg4,3,7(Suzuki, Kubota et al. 2007).  Together, these systems enable the 
formation of molecular complex on Atg16L and the subsequent insertion of LC3 in the 
membrane of PAS (Kang, Zeh et al. 2011).   
       
As mentioned earlier, the autophagy machinery is the result of many different 
complex signalization pathways.  The most characterized of these is focuses on mTOR 
(Mamalian Target of Rapamycin).  MTOR is a kinase that plays a crucial role in the 
coupling between the energetic cellular stage and the anabolic/catabolic balance.  
Although both mTORC1 and mTORC2 exists, only mTORC1 is sensitive to rapamycine 
and plays a role in autophagy.  As an important metabolic sensor, activated mTOR 
prevents autophagy to rather favor protein synthesis.  However, in a situation of 
starvation and energy deficit, inhibition of mTORC1 leads to autophagy signalization 
in coordination with other signaling pathways such as FOXO3a-NFkB, which 
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regulates transcription of autophagic regulated genes.  The mTOR complex goes on to 
link itself to Unc-51-like kinase1 (ULK1) and Atg proteins enabling initiation and 
elongation before disassociating itself to bind to the endoplasmic reticulum (ER) 
(Laplante and Sabatini 2012).  Inactivation of mTORC1, in state of starvation prevents 
the phosphorylation of mATG13, thus enabling formation of complex ULK1- mATG13-
mATG17 (Lv, Huang et al. 2014).  This shows the critical role of mTOR as a regulator 
in the autophagy process as a whole.   
 
The specific orientation and localization in the intracellular space of mTORC1 
is necessary and enabled by phosphatidylinositol-3-phosphate (PI(3)P) at the 
membranes.  Pi(3)P formation results from PI3Kinase-III Vps34, which is recruited at 
PAS due to ULK1 Beclin-1 complex, which itself is recruited to the ER.  The Beclin1 
Vps34 complex is thus crucial in the process resulting in elongation of the 
phagophore.   
 
After the phagophore has completed the elongation process, its membrane 
extremities fuse together enabling it to close and become an autophagosome.  During 
this closing process, the phagophore is slightly modified to allow its fusion with the 
lysosome once it has become an autophagosome.  One of the most important 
modifications stated above consists of the cleavage of LC3 proteins of the outside 
membrane of the autophagosome by ATG4 (Kirisako, Ichimura et al. 2000).   
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There are many proteins that play the role of fixation adaptors to the 
membrane and facilitate the fusion of the autophagosome to the lysosome.  For 
example, Rab7-interacting lysosomal protein (RILP) causes RAB7 to allow for the 
formation of tubules between the autophagosome and the lysosome, while FYCO1 
activates RAB7 enabling the transfer of the autophagosome to the lysosome along 
these tubules (Harrison, Bucci et al. 2003).  Another example of fixation adaptor 
protein is TECPR1, which enables the elongation process by allowing the interaction 
between ATG5-ATG12 and PI3P (Chen, Fan et al. 2012).   
 
Another important group of proteins that play an essential role in the fusion 
process are lysosomal-associated membrane proteins LAMP1 and LAMP2.  In fact 
these proteins are adaptors at the interface between the lysosome and 
autophagosome.  Interestingly, animal KO studies have only shown a strong 
autophagosome accumulation in LAMP2 KO (Jager, Bucci et al. 2004).   
 
After the autophagosome has completely fused to the lysosome, the damaged 
organelles are degraded by many hydrolases, lysosomial proteases as well as the 
acidic environment found in these organelles.   
 
While autophagy is necessary to ride the cell of its damaged organelles, excess 
autophagy is equally detrimental.  For this reason, there are many mechanisms of 
autophagy inhibition although most are still misunderstood.   
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An important mechanism of autophagy inhibition is sequestration of BECLIN-
1 at the endoplasmic reticulum surface by BCL2 proteins such as BCL2 and BCL-Xl, 
which are more commonly known for their anti-apoptotic behavior (Bonnefoy-
Berard, Aouacheria et al. 2004).  While BCLs can inhibit autophagy by linking itself 
and sequestering Beclin, it is unable to do so in a situation of cellular stress or lack of 
energy.  It was also recently discovered that the interaction between BCL2 and 
BECLIN-1 requires nutrient-activated autophagy factor-1(NAF-1).  In fact, studies 
showed ablation of NAF-1 prevents BCL-2 from linking to BECLIN-1, thus stimulating 
autophagy (Chang, Nguyen et al. 2010).       
 
There are many other mechanisms by which autophagy can be inhibited at all 
different steps of the autophagic process.  While MTOR can inhibit autophagy at the 
induction stage, PI(3)P dephosphorylation, BCL-2 and NAF-1 prevent formation of 
the previously mentioned PAS.  Autophagy can also be inhibited at the elongation 
process.  For instance, the FLIP protein limits lipidation of LC3, preventing the 
elongation process to take place (Khalfan and Klionsky 2002).   
  
Although its exact mechanisms are still unknown, autophagy has been shown 
to play a major role in cardioprotection by disabling damaged proteins to overly harm 
their cellular environment (Cuervo, Bergamini et al. 2005).  Lysosomes have been 
shown to be critical for adequate heart functioning.  In fact, deficiencies in lysosomal 
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degradation capacities resulted in dilated cardiomyopathies.  Defects related to 
mutations of lysosomal-associated membrane proteins have also been shown to 
cause acute cardiomyopathies just like in Danon disease (Axe, Walker et al. 2008) 
(Itakura and Mizushima 2010) (Klionsky, Baehrecke et al. 2011).   
 
The cardioprotective role of autophagy has also been studied in pre-
conditioning situations.  Many of the agents used to mimic pharmacological 
conditioning are potent sources of autophagy.  In chronically ischemic environments, 
autophagy has been found to be upregulated and cardioprotective (Gustafsson and 
Gottlieb 2008).  
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Figure 4: Macro-Autophagy pathways 
 
 
Figure 4: Macro-Autophagy pathways 
Here is a depiction of macro-autophagy and its pathways. Image taken from Maiuri et al. 2007. 
Steps 1 is represented by stages 1 and 2; step 2: 3,4; step 3:5 and step 4:6. 
1.3.2 Mitophagy 
 
While autophagy can be non-selective, it can also target specific organelles that 
are dysfunctional in order to selectively degrade them.  Since mitochondria have such 
a pivotal role in pathologies, it isn’t surprising that they have their own quality control 
mechanism.  In this section, we will elaborate on the particular mechanisms behind 
the specific degradation of damaged mitochondria. 
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Autophagy of mitochondria has been termed mitophagy.  Although healthy 
mitochondria (efficiently produce ATP, have respectable membrane potential, don’t 
produce much ROS, have few modified proteins, and have good amounts of OPA-1), 
undergo fusion and fission cycles, damaged mitochondria are excluded from the cycle 
and are discarded by autophagy.  While mitophagy was first discovered in yeast, its 
mechanisms are fairly misunderstood.  One study determined that the mitochondrial 
protein Uth1p played a role in mitophagy since mitochondrial degradation was 
delayed in its absence while the autophagic machinery remained active (Kissova, 
Deffieu et al.2004).  Other studies in yeast showed that regulatory intermediates such 
as Atg32 must also play a role in mitophagy since its mutant cell counterpart prevents 
mitophagy (Kanki, Wang et al.2009) (Okamoto, Kondo-Okamoto et al. 2009).     
 
Experiments have shown that photodamaged mitochondria were selectively 
captured by autophagosomes.  Membrane potential is important for the importation 
of mitochondrial proteins.  It is thus necessary to have high enough membrane 
potential to replace damaged proteins (Kubli and Gustafsson 2012).  
1.3.2.1 Role of Parkin in mitophagy 
In mammals, there are two distinct pathways leading to mitophagy and both 
of these pathways are activated by the depolarization of the mitochondrial 
membrane.  The first pathway requires adaptors at the mitochondrial membrane, 
while the second pathway simply relies on receptors of autophagy.  Inhibition of 
complex 1 of the ETC by a meperidine derivative (MPTP) caused Parkinsonian 
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syndrome (Langston, Ballard et al. 1983).  After similar symptoms were discovered 
in models without the Park 2 gene, a clear relation was discovered between Parkin 
and mitochondria (Greene, Whitworth et al. 2003).  Coded by Park2, Parkin is an E3-
ligase that was then studied in mammals because it’s mutation in humans were 
associated with early onset familial forms of Parkinson’s disease (i.e 10% of all 
Parkinson’s cases) (Greene, Whitworth et al. 2003).   
 
It is a protein ligase that consists of a 60 amino acid linker surrounded by an 
N-terminal ubiquitin-like domain and four zinc-finger domains.  Although its role is 
misunderstood, Parkin is mostly studied for its impact on bioenergetics and 
mitochondrial quality control (Exner, Lutz et al. 2012).  The relation between Parkin 
and mitochondrial maintenance was introduced by loss of function mutations in 
Drosophila melanogaster (Greene, Whitworth et al. 2003).    In fact, Parkin gets 
recruited to depolarized mitochondria to engage its elimination by specialized 
autophagy (mitophagy) (Geisler, Holmstrom et al. 2010, Narendra, Kane et al. 2010) 
(Vives-Bauza, de Vries et al. 2010).  Narendra et al. showed that overexpression of 
Parkin used mitophagy to remove mitochondria that had lost their membrane 
potential (Narendra, Jin et al. 2010).  Since Parkin selectively binds itself to damaged 
mitochondria, it is believed to be a key player of mitophagy (Grenier, McLelland et al. 
2013). 
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Upon studying Parkin in mammals, the protein was found to be located in the 
cytosol but recruited to the mitochondria to lead to its degradation.  In order to prove 
that Parkin’s autophagic role was specific to the mitochondria, similar in vitro assays 
were conducted in cells, in which the initiation step of autophagy was inhibited (ATG5 
KO).  This study showed that Parkin is in fact enabling autophagy specifically at the 
mitochondrial level (Scarffe, Stevens et al. 2014).   
  
To better understand Parkin’s role in mitophagy, one must understand its 
interaction with Pink1 as depicted in figure 5.  Pink1 consists of a mitochondrial 
serine/threonine-protein kinase that is also mutated in recessive cases of PD 
(Valente, Salvi et al. 2004). Its role is to protect cells from mitochondrial damage. 
Pink1 is and upstream regulator of Parkin function since overexpression of Parkin 
can salvage the phenotype of Pink1 knockout whereas overexpression of Pink1 is 
incapable of salvaging the absence of Parkin (Clark, Dodson et al. 2006).  Many other 
studies have showed that Pink1 must be present in order for Parkin to be recruited 
to the damaged mitochondria (Geisler, Holmstrom et al. 2010) (Narendra, Kane et al. 
2010) (Vives-Bauza, de Vries et al. 2010).  
 
The Pink1/Parkin pathway depends on the state of the mitochondrial 
membrane potential.  In normal mitochondria, Pink1 makes its way to the inner 
membrane by the TIM/TOM complex and is cleaved and degraded.    However, in 
mitochondria without membrane potential, Pink1 positions itself on the outer 
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membrane of the mitochondria and recruits Parkin (Narendra, Tanaka et al. 2008, 
Narendra, Jin et al. 2010) (Lazarou, Jin et al. 2012).   The Pink1/Parkin complex 
initiates autophagic degradation of the peroxisome specific to the mitochondria 
(mitophagy) by ubiquitilating outer mitochondrial membrane (OMM) proteins that 
go on to recruit other proteins to initiate mitophagy (Chan, Salazar et al. 2011) 
(Geisler, Holmstrom et al. 2010) (Lee, Nagano et al. 2010) (Narendra, Jin et al. 2010) 
(Tanaka 2010) (Yoshii, Kishi et al. 2011).  
 
In studies where Pink1 was mutated, Parkin wasn’t recruited (Geisler, 
Holmstrom et al. 2010) (Okatsu, Saisho et al. 2010) (Vives-Bauza, de Vries et al. 2010).  
The detail mechanisms behind the recruitement of Parkin by Pink1 aren’t 
understood.  Some suggests a physical interaction between Pink1 and Parkin by in 
vitro co-immunoprecipitation (Sha, Chin et al. 2010).  The nature of the substrates 
that are polyubiqitinated by Parkin is also unknown.  Some of these have been 
identified such as VDAC, Mfn 1/2, and Bcl-2. (Geisler, Holmstrom et al. 2010) 
(Narendra, Jin et al. 2010) (Gegg, Cooper et al. 2010) (Chen, Gao et al. 2010). 
 
Once Parkin transports dysfunctional mitochondria to the perinuclear region, 
p62 colocalizes to the mitochondria and enables autophagy by attaching to LC3 for 
regular autophagic degradation (Okatsu, Saisho et al. 2010).   
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However, research has shown that p62 is dispensable leading to believe in 
alternative pathways such as Nix/BNIP3L and BNIP3 (Hanna, Quinsay et al. 2012).   
When the mitochondrial membrane is depolarized, BNIP3 and NIX, proteins with a 
BH3 profile like the BCL-2 family of proteins, are recruited to the mitochondrial 
membrane (Chen, Ray et al. 1997).  These proteins are monitored by HIF-1 (cellular 
hypoxia sensor) and FOXO3 in starved cells (Zhang, Bosch-Marce et al. 2008) 
(Mammucari, Milan et al. 2007).  Upon membrane depolarization, NIX and BNIP3 
recruit LC3, which is stabilized by LIR.  FUNDC1 is also a mitochondrial protein 
activated by hypoxia and capable of recuiting LC3II (Liu, Feng et al. 2012).   
 
Mitophagy is also thought to be enabled by cardiolipins.  These phospholipids 
of the inner mitochondrial membrane move to the outer membrane following a 
depolarization and directly recruits LC3-II.  It is important to note however that 
cardiolipin induced mitophagy seems to result more from dysfunctions in the 
complexes of the respiratory chain and mitochondrial integrity than depolarization 
itself (Chu, Ji et al. 2013). 
 
Mitophagy consists of a system of degradation specific to the mitochondria and 
can result from different situations.  In fact, mitophagy can come as a consequence of 
oxidative stress from hypoxia, starvation or mitochondrial dysfunctions.             
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Figure 5: Mitophagy and the Pink1/Parkin pathway 
 
 
Figure 5: Mitophagy and the Pink1/Parkin pathway 
Here is a brief depiction of mitophagy and its pathways.  The image was taken from Scherz-Shouval 
et al. 2011. 
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1.4 Mitochondrial dysfunctions in cardiotoxicity model to anthracyclines 
1.4.1 Doxorubicin short term-cardiotoxicity and long term heart failure 
 
Cancer is characterized by uncontrolled cellular proliferation resulting in the 
formation of tumors.  The general objective of anti-cancer therapies, is to interfere 
with key processes involved in cellular proliferation, in order to promote 
commitment of cancer cells to apoptotic or necrotic cell death or senescence. 
However, due to the relative inefficacy in targeting anti-cancer drugs specifically to 
tumors, most chemotherapeutic treatment induce collateral damage in healthy 
tissues and organs. 
 
Doxorubicin is a common chemotherapy compound used for the treatment of 
several cancers including lymphoblastic and myeloblastic leukaemias, 
neuroblastomas, bone marrow sarcomas, malignant lymphomas, and carcinomas of 
the thyroid, breast, and bladder cancer.  Doxorubicin is a member of the  
anthracyclines, family of natural antibiotics which display a planar ring structure that 
facilitates its integration in the DNA double helix resulting in the inhibition of DNA 
replication and transcription in dividing cells (Gewirtz 1999).  
 
Due to its relatively short half-life doxorubicine is preferably administered 
intravenously.  In human, the treatment is usually given over a 3-4 week interval and 
does not exceed a cumulative dose of 450-550 mg/m2 because of the exponentially 
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proportional risk of heart failure (Swain, Whaley et al. 2003).    Indeed, acute cardiac 
failure occurs in about 20% of cases, for patients that receive doses exceeding 500 
mg/m2 (Swain, Whaley et al. 2003).  However, at lower doses, cardiac dysfunctions 
can occur at later stages of the treatment or even up to 20 years post treatment 
depending on the patient. Strategic dosage control has actually attenuated 
doxorubicine cardiotoxicity. However, long-term complications are common and 
drug interaction can also accentuate damages.  Currently, the lack of understanding 
of the pathogenic mechanisms underlying antracycline-induced cardiotoxocity 
remains an obstacle to the development of cardioprotective countermeasures (Swain, 
Whaley et al. 2003) (Zhang, El-Sikhry et al. 2009).   
 
Rodent models generally recapitulate key features of the cardiac disease 
observed in patients following both acute and chronic treatment.  For instance, in 
mice, left ventricular pressure is significantly reduced following acute treatment with 
15mg/kg/day of doxorubicin for 3 days (Zhang, Shi et al. 2009). An increase in 
telesystolic diameter is also observed following chronic treatment with 1.5 or 3 
mg/kg/week doxorubicin during 5 weeks followed by a 2 week wash-out period 
(Zhang, Shi et al. 2009). The availability of these models allowed to investigate the 
cellular mechanisms underlying cardiac toxicity. 
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1.4.2 Impact of Doxorubicin on mitochondria 
 
Among the mechanisms identified, mitochondrial dysfunctions are suggested 
as one of the major contributor. Indeed, several studies have shown that Doxorubicin 
accumulates in mitochondria where it promotes oxidative stress, which in turn 
induces several deleterious consequences such as: oxidative damage to proteins, 
lipids, and mtDNA, reduction of ETC and Krebs cycle enzymes activity, respiratory 
impairments, increase propensity to opening of the PTP, and activation of 
mitochondria-dependent cell death signalling (Yen, Oberley et al. 1999) (Santos, 
Moreno et al. 2002) (Serrano, Palmeira et al. 1999).   
1.4.2.1 Oxidative stress 
 
Excessive generation of ROS is a critical factor underlying the cardiotoxic effect 
of doxorubicin. Initially, supports for this hypothesis came from studies showing that, 
5-Iminodaunorubicin, which does not lead to excessive ROS production had no 
adverse effect on mitochondrial and cardiac functions (Davies and Doroshow 1986). 
Further mechanistic studies revealed that doxorubicin entertains a futile redox cycle 
at the level of complex 1 of the respiratory chain, where it allows production of 
semiquinone intermediates (Davies and Doroshow 1986), which are oxidized to form 
highly reactive superoxide anions that overwhelm mitochondrial antioxidant 
capacities. 
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This effect of doxorubicin is facilitated by the fact that this drug displays a 
particular affinity for mitochondrial lipids, particularly cardiolipin.  Owing to this 
affinity, doxorubicin readily insert itself in the mitochondrial membranes, where it 
promotes lipid peroxidation (Huart, Brasseur et al. 1984). Malondialdehyde (MDA) 
levels, a known marker of lipid peroxidation, are increased by nearly threefold in 
heart mitochondria from rats treated with 6 injections of 2.5mg/kg i.p. of doxorubicin 
over a 2 week period (Arafa, Mohammad et al. 2014). The accumulation of oxidative 
stress is also evident in mitochondrial DNA in comparison to the nuclear DNA.  
Indeed, after acute doxorubicin intoxication, studies revealed a 2-fold increase in 8-
hydroxy-2’deoxyguanosine (8OHdG) adducts, a marker of DNA oxidative damage, in 
mitochondrial DNA relative to nuclear DNA, which clearly support preferential 
oxidative damage to mitochondria. Studies also show that mitochondrial 
dysfunctions and oxidative damage to mtDNA persists five weeks after an 8 week 
treatment with doxorubicin (Serrano, Palmeira et al. 1999), illustrating the fact that 
damage incurred at the level of the electron transport chain, particularly complex I 
enables a self-perpetuating cycle of oxidative stress weeks following the last injection.         
 
1.4.2.2 Cellular respiration impairments caused by oxidative stress (ETC, Kreb cycle 
enzymes and respiratory impairments)  
 
As mentioned above, doxorubicin-induced oxidative stress can lead to the 
inhibition of ETC and Krebs cycle enzymes, ultimately resulting in respiratory 
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impairments. For instance, exposure of isolated mitochondria to doxorubicin was 
shown to lead to a 35% decrease in complex I activity (4.5  ± 0.6 vs 7.0  ± 0.9 
nmol/min/mg) (Santos, Moreno et al. 2002) resulting in a 20 % decrease in ADP-
stimulated state 3 respiration (336 ± 26 vs 425 ± 53 natoms O/min/mg), but no 
changes in basal state 4 respiration in presence of substrates for complex I. Similarly 
Solem et al. reported a significant reduction of state 3 respiration (358 ± 81 vs 529 ± 
48 natoms O/min/mg protein), reduced respiratory control ratio (RCR) (5.2 ± 1.3 vs 
9.3 ± 0.6) and no change in basal complex I-driven state 4 respiration following 
treatment with doxorubicin  (Solem, Henry et al. 1994).  Another study in mice 
treated with doxorubicin reported similar observation. However, this study also 
reported that doxorubicin led to reduced complex II activity and thus impaired state 
3 respiration and RCR in presence of the complex II substrate succinate (Yen, Oberley 
et al. 1999).  
 
Doxorubicin treatment was also shown to inhibit respiratory chain activity 
even more severely when coupled in an iron complex.  Indeed, in a study performed 
on pig-heart submitochondrial particles, respiratory chain activity was severely 
inhibited following administration of an adryamicyn-Iron complex as compared to 
10-15% when doxorubicin was administered alone (Demant and Jensen 1983).  
 
Studies have also showed a clear correlation between the extent of lipid 
peroxidation and respiratory chain inhibition reinforcing the impact of mitochondrial 
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oxidative stress in doxorubicin-induced respiratory impairments (Demant and 
Jenson 1983 & Praet et al, 1984). 
 
1.4.2.3 Mitochondrial permeability transition 
 
In addition to the above-mentioned impairments, histopathological analyses 
have shown that acute and chronic treatments with doxorubicin leads to significant 
disorganization of mitochondrial structure, and an abnormal swelling of the matrix. 
(Zhou, Palmeira et al. 2001), which is a typical consequence of mitochondrial 
membrane permeabilization following opening of the PTP.  Furthermore, electron 
microscopy studies showed that doxorubicin treatment leads to the formation of 
calcium hydroxyapatite deposits in cardiomyocytes, which localize to mitochondria 
(Aversano and Boor 1983), further pointing to calcium overload as a trigger for PTP 
opening. Direct measurement of susceptibility to Ca2+-induced opening of the PTP in 
isolated mitochondria have repeatedly shown that doxorubicin treatment 
significantly increases susceptibility to PTP opening (Zhou, Starkov et al. 2001). This 
susceptibility has been ascribed to the well-established role of oxidative stress in 
sensitizing the PTP to Ca2+ (Chacon and Acosta 1991) (Zoratti and Szabo 1995). 
 
Studies with cyclosporine-A, the prototypical partial inhibitor of the PTP, 
suggest that opening of the PTP plays an important role in doxorubicin-induced 
cardiotoxicity. Indeed, administration of cyclosporine-A to doxorubicin-treated rats 
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prevent the reduction of Ca2+-retention capacity, an indicator of the propensity to PTP 
opening. Cyclosporin-A was also shown to blunt the sensitization to Ca2+-induced 
mitochondrial depolarization observed following treatment with doxorubicin 
(Solem, Henry et al. 1994) (Solem and Wallace 1993). 
 
Overall, it is therefore clear that doxorubicin induces multiple mitochondrial 
abnormalities encompassing oxidative damage to lipids, proteins and DNA, which 
ultimately impairs bioenergetics function and promotes triggering of cell death 
through opening of the PTP. Consequently, mitochondria are increasingly viewed as 
targets for interventions aimed to limit the cardiotoxic effects of antracyclin-based 
chemotherapy. Currently proposed strategies include mitigation of oxidative stress 
using mitochondria-targeted anti-oxidants and prevention of PTP opening using 
cyclosporine-A derivatives. Furthermore, with the recent discovery of mitochondrial 
quality control mechanisms such as mitophagy, targeting of these processes is 
emerging as a future therapeutic avenue to limit mitochondrial dysfunction. 
However, the role of mitophagy in the heart remains largely unexplored and it is 
currently unclear whether modulation of this process can have an impact on disease 
trajectory. 
  
2 RESEARCH HYPOTHESIS AND OBJECTIVES: 
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 My research hypothesis consists that the deficit of mitophagy in Parkin -/- 
would cause an exacerbation of mitochondrial dysfunctions normally induced by 
doxorubicin.  In order to verify this hypothesis, we submitted Parkin deficient mice 
to an acute treatment of doxorubicin and analyzed the impact of genotype and 
treatment on morphology and cardiac functions, diverse mitochondrial functions as 
well as mitochondrial content and enzymatic activity.   
 
   
 
3 EXPERIMENTAL STUDY 
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3.1 Methodology 
3.1.1 Animals 
 
The animal ethics committee of the University of Montreal in conjunction with 
the Canadian Council of Animal Care approved all the experimental protocols used.  
Wild type (WT) and Parkin-deficient (Parkin-/-) mice from INSERM-Sanofis-
Adventis(Chen, Xu et al. 2011) were taken care of and kept at the Institut de 
Recherche en Immunologie et en Cancérologie (IRIC) of the University of Montreal.  
The precise n number used for each experiment is indicated in the figure legend.  Mice 
ranging eight to twelve weeks old were injected i.p with doxorubicin (15mg/kg) or 
with PBS (vehicle) because these doses had been shown to cause mitochondrial 
toxicity (Palmeira, Serrano et al. 1997).  Injections were made at 0 and 48 hours to 
emulate the injection timing used in this acute setting (Kawaguchi, Takemera et al. 
2012).  Animals were then used for experiments five days following the last injection 
to see if Parkin might have a protective property as established previously in the lab 
(Piquereau, Godin et al. 2013).  Body weight was monitored daily.  Animals were then 
anaesthetized for echocardiography and euthanized by cervical dislocation.    Hearts, 
lungs and livers were rapidly excised and weighed. Subsequently, hearts were either 
flash frozen and stored in a -80°C freezer or immediately used for the preparations of 
permeabilized cardiac fibers. 
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3.1.2 Echocardiography 
Mice were sent to the Lady Davis institute for a week for acclimation to their 
new environment.  The following week, mice were subjected to the Doxorubicin 
treatment protocol as described above.  Cardiac morphology and functions were 
analyzed in anesthetized mice by echocardiography 
 
3.1.3 Permeabilized heart fibers 
Left ventricles were removed and placed into pre-cooled buffer A (inmM: (2.77 
CaK2EGTA, 7.23 K2EGTA, 6.56 MgCl2, 0.5 dithiothreitol (DTT), 50K-MES, 20 imidazol, 
20 taurine, 5.3 Na2ATP, 15 phosphocreatine, pH7.3 at 4°C).   Small fiber bundles of 
the left ventricule were manually dissected under a microscope and permeabilized 
with saponin (50ug/ml) for 30 minutes.  Fiber bundles were then washed three times 
for 10 minutes in buffer B (in mM:2.77 CaK2EGTA, 7.23 K2EGTA, 1.38 MgCl2, 3.0 
K2HPO4, 0.5 dithiothreitol, 20 imidazole, 100 K-MES, 20 taurine, pH 7.3 at 4°C) 
supplemented with BSA (2 mg/ml) and kept on ice until respirometry is performed 
and analyzed.  In terms of the ghost fibers without myosin, they were permeabilized 
with saponin and washed three times in Buffer B.  They were then washed three times 
for 10 minutes in Buffer C (in mM: K-MES 80, HEPES 50, taurine 20, DTT 0.5, MgCl2 
10, pH 7.3 at 4°C) and incubated for 30 minutes with agitation at 4°C in Buffer D (in 
mM: KCL 800, HEPES 50, taurine 20, DTT 0.5, MfCl2 10, ATP 10, pH 7.3 at 4°C) to 
extract myosin.  The bundles were finally washed three times in low-EGTA sucrose 
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buffer (in mM: 250 sucrose, 10 Tris base, and 0.1 EGTA, pH 7.4) and kept on ice until 
Ca2+-induces PTP assays (Picard, Csukly et al. 2008). 
 
3.1.4  Mitochondrial respiration 
Fibers (about 0.3mg dry) bathed in specify volume solution B (in mM: 2.77 
CaK2EGTA, 7.23 K2EGTA (100nM free Ca2+), 6.56 MgCl2 (1mM free Mg2+), 20 taurine, 
0.5 DTT, 50 K-methane sulfonate (160mM ionic strength), 20 imidazole, pH 7.1)) 
were used to determine mitochondrial respiratory function.  Respiration was 
measured using Clark type electrodes at 25 oC under continuous low speed magnetic 
stirring (5% of maximal speed).  Respiratory rates were measured at each step of the 
following sequence of substrates and inhibitors: the complex I substrates glutamate-
malate (GM)(5, 2.5mM); ADP (2mM); complex I inhibitor amytal (2mM); the complex 
II substrate succinate (5mM); the uncoupler CCCP (1μM); the complex III inhibitor 
antimycin-A (AA) (8μM); the complex IV substrates N, N’, N’- tetramethyl-p-
phenylenediamine dihydrochloride (TMPD)-ascorbate (0.9mM, 9mM); and the 
complex IV KCN (0.6mM). This sequence allowed determining the respiratory 
performance of mitochondria using specific segments of the electron transport chain 
as well as various respiratory states including baseline, maximal ADP-stimulated and 
uncoupled respiration. 
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3.1.5 Mitochondrial ROS production 
Fibers (about 0.5mg dry) bathed in specify volume solution Z (in mM: 110 K-
MES, 35 KCl, 1 EGTA, 5 K2HPO4, 3 MgCl26H2O, 0.5mg/ml BSA, 1.2U/ml horseradish 
peroxidase, pH 7.3, 37°C) supplemented with the fluorescent probe Amplex 
Red(20μM: excitation-emission: 563-587nm) were used to determine mitochondrial 
hydrogen peroxide (H2O2) release(Ascah, Khairallah et al. 2011).  Release of H2O2, 
was measured by fluorescence spectroscopy in quartz microcuvettes under 
continuous magnetic steering.  Fluorescence was first read at baseline and substrates 
were then added sequentially as follows: glutamate (5mM); succinate (5mM); ADP 
(10mM); and antimycin-A (8μM).   
 
3.1.6 Calcium rentention capacity (CRC) 
 
Ghost fibers (about 0.5mg dry) incubated at 23°C bathed in specify volume 
CRC solution (in mM: 250 sucrose, 10 MOPS, 0.005 EGTA, 10 Pi-Tris, pH 7.3) in a 
quartz microcuvette with continuous magnetic stirring. To this was added: 
glutamate-malate (GM) (5:2.5mM) and 0.5nM oligomycin and the fluorescent probe 
calcium green (5N: excitation –emission: 505-535nm) in order to determine calcium 
retention capacity of mitochondria(Picard, Csukly et al. 2008).  After adding the 
previous substrates, a pulse of 20 nmol calcium (Ca2+) was added to determine CRC 
per mg of dry fiber weight in the cuvette,.  CRC refers to the amount of calcium 
accumulated in mitochondria before their PTP opens and releases it. Concentration 
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of calcium was calculated in relation to the standard curve relating calcium 
concentration to fluorescence of calcium-green.   
3.1.7 Enzymology 
The enzymatic activities of citrate synthase (CS), aconitase, complex I, complex 
II, complex I+III, and complex IV were measured by spectrophotometry on a plate 
reader using enzyme-coupled assays (Marcil, Ascah et al. 2006, de Wit, Scholte et al. 
2008).  The enzymatic activities were all given in mU/min/mg of protein except for 
aconitase, which was expressed in mU/min/mg/mg tissue.  Each complex is given a 
specific substrate enabling us to read absorption differences over a period of time.   
 
Citrate synthase (CS) consists of the first enzyme in the Krebs cycle that 
transforms acetyl-CoA and oxaloacetate into citrate and releases CoA-SH.  The change 
in absorbance of DTNB at 412nm depicts the CS activity and the buffer used consisted 
of 100mM Tris 200mM, 200mM Acetyl CoA, 200mM DTNB, 1% Triton X-100 10% and 
water.  The disulfure brigde of DTNB is cleaved by the thiol part of CoA-SH and 
produce 2 NTBs.  These DTTBs ionise in water and emit a yellow coloration that can 
absorb light at 412nm.  The molecular coefficient of extinction of DTNB is 13.6 Lmol-
1cm-1. 
Equation:   ܣܿݐ݅ݒ݅ݐݕܥܵ݅݊ܷ݉Ǥ݉݃ିଵ ൌ ቂሺௌ௟௢௣௘כᇞ஽ሻሺఌெൈ௟ሻ ቃ ൈ ቂ
௏
௠ቃ 
 
Complex 1 (CI) activity is measured by changes in absorbance of NADH at 
340nm.  Complex 1 oxydizes NADH into NAD+.  The buffer used consisted of 50mM-
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2mM of KPi buffer 50mM, 1mg/mL BSA, 250mM KCN, 200mM NADH, 0.4mM 
Antimycine A (AA) and 100mM of Decylubiquinone.  In order to isolate CI, AA and 
KCN inhibit CIII and CIV respectively.  Finally, CI is inhibited with 20mM rotenone at 
the end of the reaction to correct for CI-independent NADH oxidation.  CI enzymatic 
activity is the difference between the two slopes obtained.  The equation is the same 
as the one used to calculate CS and the molar coefficient of extinction of NADH at 
340nm is 6220 Lmol-1cm-1. 
 
The activity of Complex 2 (CII) corresponds to the variation of absorption of 
DCIP @ 600nm.  The buffer used to measure the enzymatic activity of CII consists of 
50mM-2mM of KPi-EDTA tampon 50mM-2mM, 1mg/mL BSA, 240mM, Rotenone 
4mM, AA 0.4mM, 100mM Decylubiquinone, DCIP 100mM, Succinate 10mM and ATP 
2mM.  The oxidation of succinate and decylubiquinone by CII enables the reduction 
of DCIP.  The electron flux is inhibited by inhibition of CI by rotenone and inhibition 
of CIV by KCN. Malonate 10mM is then added to inhibit CII and correct the slopes by 
measuring the autoreduction of DCIP.  The molar coefficient of extinction of DCIP is 
16.3 Lmol-1 cm-1 and the equation to calculate the enzymatic activity of CII is the same 
as the one for CS. 
 
The activity of complex I+III consists of the increase of absorbance of 
cytochrome c due to its reduction. The buffer used consists of KPI, BSA 1mg/ml, 
NADH 0.8mM, cytochrome c 40uM, 0.4mM KCN and rotenone 4uM. NADH donates 
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electrons to complex I before being transferred to complex III, which enables the 
latter to reduce cytochrome c.  The KCN is used to inhibit complex IV and prevent the 
oxidation of cytochrome c, which has a molar coefficient of extinction of 29.5mM-1.  
Rotenone is also added in order to block complex I.  The difference in the slopes prior 
and after adding rotenone represents the enzymatic activity of complex I+III.         
 
CIV activity is measured by the decrease in absorbance of oxidized cytochrome 
c by CIV.  To get this measurement, we must start by giving CIV reduced and purified 
cytochrome c. The buffer used to measure CIV is composed of 50mM KPi buffer 
25mM, dodecylmaltoside 0.1% and cytochrome c 100mM.  Finally, the molar 
coefficient of extinction of DCIP is 29.5 lmol-1cm-1 and the equation is once again the 
same as the one to calculate CS.     
3.1.8 Statistical analysis 
All results are expressed as mean ± SEM. For statistical analysis 2-way ANOVA 
tests were used to compare the effect of the genotype and doxorubicin treatment. 
Bonferonni’s multiple comparison tests were performed to determine where the 
differences were located. A P value of  P<0.05 was considered statistically different. 
All analyses were performed using Prism 6.0 (GraphPad Sofware). 
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3.2 Results 
3.2.1 Echocardiography and morphometric analyses 
Figure 6 summarizes the impact of Parkin deficiency and doxorubicin 
administration on mice morphometric parameters. At baseline, Parkin-deficient mice 
had a 9.5% smaller body weight compared to the WT mice (p=0.049*). The weight of 
the heart, liver and lungs also tended to be lower in Parkin-deficient mice, consistent 
with the lower body weight. In WT mice, treatment with doxorubicin led to an almost 
significant 1.2 % loss of body weight (p=0.06). Heart, lung and liver weights were not 
significantly changed following treatment with doxorubicin. As opposed to WT mice, 
treatment with doxorubicin in parkin-deficient mice did not show a reducing trend in 
variation of body weight.  After treatment with doxorubicin in WT mice, only body 
weight showed a strong reducing trend, while doxorubicin had no noteworthy effect 
in Parkin-deficient mice. 
Figure 7 presents results from preliminary echocardiography analyses. At 
baseline, we observed no difference between WT mice and Parkin-deficient mice in 
terms of their cardiac index and ejection fraction, which is in agreement with our 
previous results obtained with Millar catheterization (Piquereau, Godin et al. 2013).      
End systolic and diastolic volumes tended to be lower in Parkin-deficient mice, but no 
significant difference could be detected with the limited sample size available (n=3 in 
each group).  After treatment with doxorubicin, there were no significant differences 
in the cardiac index and ejection fraction in both WT and Parkin-deficient mice.  
However, WT mice displayed a reducing trend of left end-systolic and diastolic 
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ventricular volume following treatment with doxorubicin, while these changes were 
less apparent in Parkin-deficient mice, likely due to the variability observed in 
baseline volumes.  Mitochondrionopathy can precede cardiotoxicity in certain cases 
preventing the observation of cardiac dysfunction following treatment with 
doxorubicin (Pereira, Pereira et al. 2012).  This lack of effect was also demonstrated 
in the lab after raising the n number.    
Figure 6: Effect of doxorubicin on morphometric parameters in WT and Parkin -/- mice 
 
Figure 6: Effect of doxorubicin on morphometric parameters in WT and Parkin -/- mice.  
Doxorubicin’s effect on body weight (A) (n=8-11), heart weight (B) (n=5-8), lung weight (C) (n=3-
6) and liver weight (D) (n=3-6) were measured in both WT and parkin -/- mice. 15mg/kg of 
doxorubicin was administered by intraperitoneal injection. *, significantly different within same 
experimental conditions (P<0.05). 
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Figure 7: Effect of doxorubicin on cardiac function parameters in WT and Parkin-/- mice 
 
Figure 7: Effect of doxorubicin on cardiac function parameters in WT and Parkin-/- mice.  
Doxorubicin’s ejection fraction (A), cardiac index (B), left ventricle volume in diastole (C) and 
systole in both WT and parkin -/- mice (n=3).    
 
3.2.2 Mitochondrial Respiration 
Following these initial observations, experiments were conducted to assess 
the impact of Parkin ablation and doxorubicin treatment of various aspects of 
mitochondrial function. We first measured mitochondrial respiration in cardiac 
permeabilized fibers to study different respiratory states in presence of substrates 
feeding specific complexes of the electron transport chain. As shown in Figure 8, at 
baseline levels, there was a significant reduction in most respiratory states in Parkin-
deficient mice. In Parkin-deficient mice, respiration with substrates feeding complex 
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I stimulated by ADP (p=0.0077**), complex II (0.0064*), and complex IV (p=0.0090**) 
were all significantly lower than in their WT counterparts. Respiration at the level of 
complex I stimulated by glutamate-malate (GM) (p=0.052*) was nearly significantly 
smaller as well. In mice treated with doxorubicin, we observed a systematic reduction 
in respiration in mitochondria from WT mice (CI:p=0.0216*; ADP stimulated CI: 
p=0.0067** or CII: p=0.0029**; CIV: p=0.0066**).  However, in Parkin-deficient mice, 
treatment with doxorubicin had no negative impact on respiration under all 
conditions.  The effects of doxorubicin were completely abolished in Parkin -/- mice. 
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Figure 8: Effect of doxorubicin on mitochondrial respiration in WT and Parkin-/- mice 
 
 
Figure 8: Effect of doxorubicin on mitochondrial respiration in WT and Parkin-/- mice.  Rates 
of respiration of WT and KO mice treated and not treated with doxorubicin following sequential 
addition of: complex I substrates glutamate-malate (GM)(5, 2.5mM) (n=6-7); ADP (2mM) (n= 6); 
complex I inhibitor amytal (2mM) (not shown); the complex II substrate succinate (5mM) (n=4-6); 
chain uncoupler CCCP (1μM) (not shown); complex III inhibitor antimycin-A (AA) (8μM) (not 
shown); and the complex IV substrates N, N’, N’- tetramethyl-p-phenylenediamine 
dihydrochloride (TMPD)-ascorbate (0.9mM, 9mM)(n=3-6); complex IV KCN (0.6mM) (not 
shown).  *, significantly different within same experimental conditions (P<0.05).  **, significantly 
different (P<0.01). 
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3.2.3 Enzymology 
 
We then measured enzymatic activity of citrate synthase, aconitase, and 
complexes I, II, I+III, and IV of the respiratory chain.  At baseline, enzymatic activity 
of complexes I, and I+III showed a reducing trend in Parkin-deficient mice in 
comparison to WT mice.  However, the activity of citrate synthase, complexes II and 
IV, and aconitase, was not different between the two groups (Figure 9 and 10).  In WT 
mice, treatment with doxorubicin induced a reducing trend in the enzymatic activity 
of complexes I and I+III, while the activities of CS, complex II, and complex IV were 
not affected. As expected, doxorubicin treatment also induced a reduction in 
aconitase activity in the heart of WT mice (p=0.0270*).  In contrast, in Parkin-
deficient mice, treatment with doxorubicin did not significantly worsen the activity 
of these enzymes beyond the levels observed. 
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Figure 9: Effect of doxorubicin on citrate synthase and enzyme activity of complexes of the 
ETC in WT and Parkin-/- mice 
 
 
 
Figure 9: Effect of doxorubicin on citrate synthase and enzyme activity of complexes of the 
ETC in WT and Parkin-/- mice.  Enzymatic activities in mU/min/mg tissu of different complexes 
I (A) (n=4), I+III (B) (n=4-5), CS (C) (n=4-6), II (D) (n=4-6) and IV (E) (n=4-6) of the ETC for 
both WT and KO mice in basal conditions and treated with doxorubicin.  *, significantly different 
within same experimental conditions (P<0.05). 
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Figure 10: Effect of doxorubicin on aconitase activity in WT and Parkin-/- mice 
 
 
 
 
 
Figure 10: Effect of doxorubicin on aconitase activity in WT and Parkin-/- mice. Aconitase 
activity in WT and KO mice (n=4) in basal and doxorubicin treated conditions. *, significantly 
different within same experimental conditions (P<0.05). 
 
3.2.4 Mitochondrial H2O2 release 
Mitochondrial H2O2 release per unit of oxygen consumed was directly 
measured using the Amplex red probe. While significant differences were observed 
under different conditions tested, we focus solely on when the respiratory chain was 
fed with the complex II substrate succinate, which maximizes ROS production by 
promoting reverse electron flow through complex I.  As shown in Figure 11, under 
baseline conditions, mitochondrial H2O2 release was systematically greater in Parkin-
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deficient mice compared to WT mice under all conditions tested but significant 
differences were evident when the respiratory chain was fed with the complex II 
substrate succinate (p=0.0108).  In WT mice, treatment with doxorubicin induced a 
significant increase in H2O2 release (p<0.0001), particularly in presence of the 
complex II substrate succinate. In contrast, in Parkin-deficient mice, the increase in 
H2O2 release following doxorubicin treatment was blunted in presence of succinate. 
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Figure 11: Effect of doxorubicin on mitochondrial H2O2 release in WT and Parkin-/- mice 
 
 
Figure 11: Effect of doxorubicin on mitochondrial H2O2 release in WT and Parkin-/- mice.  
Hydrogen peroxide production per unit of oxygen consumed in WT and KO mice in basal 
conditions and post-treatment with doxorubicin following sequential addition of glutamate (5mM) 
(n=7-11); succinate (5mM) (n=6-11); ADP (10mM) (n=7-11); and antimycin-A (8μM) (not 
shown).  The data was normalized by oxygen consumed in order to accurately depict the correlation 
between oxygen consumed and ROS produced. *, significantly different within same experimental 
conditions (P<0.05). **, significantly different (P<0.01). 
 
3.2.5 Calcium Retention Capacity 
We also examined the susceptibility of mitochondria to Ca2+-induced opening 
of the permeability transition pore (PTP).  At baseline, susceptibility to PTP opening 
was greater in Parkin-deficient mice in comparison to WT mice, as evidenced by 
lower calcium retention capacities (p=0.0477*) and time to pore opening was nearly 
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significantly lower than it’s basal WT counterpart (p=0.0504).  In WT mice, treatment 
with doxorubicin significantly enhanced sensitivity to PTP opening (CRC: p=0.0259*, 
time to opening: p=0.098**). However, in Parkin-deficient mice, susceptibility to PTP 
opening was not deteriorated beyond levels observed at baseline (12).  
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Figure 12: Effect of doxorubicin on PTP opening in WT and Parkin-/- mice 
 
Figure 12: Effect of doxorubicin on PTP opening in WT and Parkin-/- mice 
Time necessary for opening of PTP (n=4-7) and calcium retention capacity (CRC) (n= 5-6) of WT 
and KO mice in both basal situation and following treatment with doxorubicin. *, significantly 
different within same experimental conditions (P<0.05). 
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3.3 Discussion 
Mitochondrial quality control mechanisms are increasingly considered as being 
central determinant of mitochondrial health in mammalian tissues, particularly in 
energy demanding tissues such as the heart where these organelles are abundant. In 
the present study we aimed to determine whether selective autophagy of 
mitochondria (i.e. mitophagy) through the Parkin-dependent pathway is required for 
the maintenance of normal mitochondrial and cardiac function, and important to 
mount adequate response to mitochondrial stress in a well-characterized model of 
antracyclin-induced cardiotoxicity. Although mitochondrial quality control was not 
formally investigated, it currently represents the main factor linking Parkin to 
mitochondrial function.  Our results show that genetic inactivation of Parkin at the 
germline level does not induce overt cardiopathy under normal baseline conditions, 
but nevertheless causes multiple but moderate mitochondrial dysfunctions, 
suggesting that Parkin participates in baseline mitochondrial quality control. As 
expected, in vivo treatment with doxorubicin induced multiple mitochondrial 
abnormalities in wild type mice that were clearly observable in absence of heart 
failure. However, in contrast to our initial hypothesis, genetic inactivation of Parkin 
did not enhance mitochondrial dysfunctions induced by doxorubicin, and even 
seemed to exert a protective effect, through mechanisms that remain to be elucidated.   
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3.3.1 Role of Parkin in the maintenance of baseline cardiac and mitochondrial 
phenotype 
Under baseline conditions, we observed that the absence of Parkin did not 
significantly impair cardiac function. Both the cardiac index and the ejection fraction 
showed no difference in Parkin-deficient mice in comparison to WT mice.  In terms of 
cardiac volumes, both the end systolic and end diastolic volumes tended to be lower 
in Parkin deficient mice compared to controls, but the difference did not reach 
statistical significance, possibly due to the small sample size inherent to these 
preliminary experiments. However, despite the absence of a clear cardiac phenotype, 
the absence of Parkin was nevertheless associated with multiple mitochondrial 
dysfunctions such as impairment of mitochondrial respiration, increased production 
of reactive oxygen species and reduced calcium retention capacity, which is indicative 
of greater susceptibility to PTP opening.  These baseline results are in line with 
previous findings from our laboratory (Piquereau, Godin et al. 2013).  It is interesting 
to note however, that a previous study by another laboratory reported no difference 
in baseline mitochondrial functions in Parkin-deficient mice compared to controls 
(Kubli, Zhang et al. 2013).  Although the reasons underlying this difference are 
unclear, one possibility is that in this latter study, measurements were performed on 
isolated mitochondria. The use of this more disruptive preparation could explain the 
differences with our laboratory’s results.  
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3.3.2 Impact of Doxorubicin on cardiac and mitochondrial function 
As expected, treatment with doxorubicin resulted in mitochondrial 
dysfunctions at multiple levels.  Our study and previously published experiments 
(Yen, Oberley et al. 1999) (Santos, Moreno et al. 2002) (Serrano, Palmeira et al. 1999)  
confirmed the ability of doxorubicin to inhibit mitochondrial respiration and trigger 
a significant rise in ROS production leading to oxidative stress and reduction in the 
threshold for calcium induced PTP opening. Interestingly, most previous studies   
(Zhang, El-Sikhry et al. 2009) have reported these mitochondrial abnormalities at 
significantly advanced stages of cardiopathy at a time when hemodynamic function 
was impaired. In contrast, in our study, our preliminary echocardiography results 
suggest that we were able to observe these changes prior to overt signs of cardiac 
dysfunction. This suggests that mitochondrial dysfunctions are not simply a 
consequence of heart failure but rather, a pathogenic mechanism.    
3.3.3 Impact of Parkin deficiency in response to doxorubicin. 
In response to treatment with doxorubicin, our study indicates that Parkin 
deficiency did not worsen mitochondrial functions and if anything, suggested a 
protective effect. In terms of morphometric analysis, Parkin deficiency blunted the 
effect of doxorubicin on animal weight loss.  Decline in cardiac mitochondrial 
functions and enzymology were also not observed in Parkin deficient mice treated 
with doxorubicin although comparison to WT mice is partly confounded by the fact 
that Parkin-KO hearts had lower mitochondrial functions to begin with.  There is also 
the possibility of a ceiling effect of the KO that may mask the effect of doxorubicin.  
     
67 
While we do not have a definite explanation for this, as discussed below, we believe 
that these data cannot be simply interpreted as an indication that mitophagy is 
detrimental in the context of doxorubicin-induced cardiotoxicity.    
3.3.3.1 Germline knockout of the Park2 gene produces a complex phenotype: 
Compensatory mechanisms add an important degree of complexity to the 
study of specific quality control mechanisms such as mitophagy.  Studies in our 
laboratory as well as other previously published experiments (Hsieh, Pai et al. 2011) 
have reported activation of macro-autophagy in myocytes following sepsis induction. 
There are two types of compensatory mechanisms related to mitophagy: i) activation 
of alternate mechanisms of mitophagy and ii) enhanced macro-autophagy.   
 
To support the role of alternate mitophagy mechanism, our laboratory has 
previously demonstrated that there is more LC3-II recruited to mitochondria in 
Parkin-deficient hearts compared to WT (Piquereau, Godin et al. 2013).  This not only 
suggests the existence of compensatory mechanisms that can protect Parkin-deficient 
mice, but it also suggests the existence of other mitophagic mechanisms then the 
Parkin/Pink-1 pathway.  As suggested by others, alternate E-3 ligases may 
compensate for Parkin-deficiency (Ding, Ni et al. 2010).  In yeast, mitophagy can also 
be achieved via a ubiquitin-independent pathway with direct binding of ATG8 family 
of mitochondrial autophagy receptors.  In yeast, this pathway requires ATG32 
receptor (Kanki, Wang et al. 2009) while in mammalian cells, NIX and BNIP3 are 
mitochondrial autophagy receptors (Novak, Kirkin et al. 2010). It is notable that both 
     
68 
NIX and BNIP3 are recruited to mitochondria in WT and Parkin-KO hearts in response 
to sepsis (Piquereau, Godin et al. 2013). Altogether, these results thus suggest the 
possibility that Parkin ablation in the heart does not overtly compromise stress-
induced mitophagy. However, this does not really contribute to explain how Parkin 
deficiency seems to attenuate the negative impact of doxorubicin observed in the 
present study. 
 
In terms of enhanced macro-autophagy, our laboratory was recently first to 
report that Parkin-deficiency is associated with an upregulation of macro-autophagy 
(Piquereau, Godin et al. 2013).  In fact, baseline transcripts of major autophagy-
regulated genes were found to have increased expression in Parkin-deficient mice 
when compared to WT.  Moreover, autophagy flux measured in vivo by the 
accumulation of LC3-II, was significantly higher in Parkin-KO hearts both at baseline 
and in response to LPS treatment (Piquereau, Godin et al. 2013).  Morphological 
experiments also confirmed the increased number of autophagosomes in Parkin-
deficient mice hearts in comparison to WT mice.  Also, large autophagosomes 
containing mitochondrial remnants, damaged cellular material and lipid droplets 
were found in Parkin KO mice but not in WT mice following LPS treatment 
(Piquereau, Godin et al. 2013). Together these data suggested that genetic 
inactivation of Parkin at the germline level results in a compensatory upregulation of 
less specific forms of autophagy. As discussed below, we believe that this constitutive 
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activation of macro-autophagy may contribute to explain the paradoxically beneficial 
effect of Parkin-deficiency in response to doxorubicin.  
 
Several studies were recently performed to examine the role of macro-
autophagy in the heart in response to stress. In mouse models, evidence suggest that 
doxorubicin blunts the autophagic process, which in turns contribute to the 
cardiopathic phenotype.  More specifically, Kawaguchi et al. reported that 
doxorubicin treatment leads to the accumulation of several autophagy makers in 
adult mouse hearts (LC3-II, P62 and Cathepsin D) and neonatal cardiomyocytes 
(Kawaguchi, Takemura et al. 2012). However, several evidence indicate that this 
accumulation is caused by reduced autophagosome clearance rather than activation 
of autophagosome formation: i) blockade of the lysosomal degradation by cloroquine 
did not further enhance LC3-II accumulation, ii) doxorubicin administration in fact 
inhibited AMPK-ULK1, a major trigger of autophagy. Moreover, starvation prior to 
doxorubicin administration was able to mitigate Doxorubicin-induced cardiac 
dysfunction, which was associated with a lower accumulation of LC3-II puncta and 
restoration of AMPK-ULK1 activation, suggesting that re-activation of autophagy was 
beneficial. Studies performed in vitro in H9C2 cardioblasts also reported that the 
autophagy inducer rapamycin mitigated doxorubicin-induced cellular toxicity 
(Kawaguchi, Takemura et al. 2012) (Sishi, Loos et al. 2013).    Therefore, it is tempting 
to speculate that in our study, constitutive activation of macro-autophagy contributes 
to explain the apparently protective effect of Parkin-deficiency in mice treated with 
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doxorubicin.   However, this hypothesis remains to be tested by measuring the 
autophagy flux of the different groups. 
  
It should be mentioned that conflicting results exist with respect to the effect 
of doxorubicin treatment on cardiac autophagy. Indeed, several studies performed in 
rat models suggest that doxorubicin treatment results in excessive activation of 
autophagy, which in turn promotes cardiac dysfunction (Lu, Wu et al. 2009) Chen, 
Kobayashi et al. 2009).  Indeed, a study by the group of Lu et al. demonstrated that 
doxorubicin stimulated cardiac autophagy (Lu, Wu et al. 2009). Rat neonatal 
cardiomyocytes treated with doxorubicin showed an increase in the number of 
autophagic vesicles.  Another group also reported that autophagy was upregulated 
following treatment with doxorubicin (Dimitrakis, Romay-Ogando et al. 2012).  
Similar to Lu et al., the latter group concluded doxorubicin resulted in excessive 
activation of autophagy based on the enhanced accumulation of autophagosomes 
following blockage of lysosomal degradation with cloroquine. Two other studies also 
reported evidences suggesting excessive activation of autophagy in rat models of 
doxorubicin cardiotoxicity. 
 
Kobayashi et al (Kobayashi, Volden et al. 2010) demonstrated a clear increase 
in autophagic flux (LC3-II/I) in cells treated with doxorubicin.  They also found an 
increase in the number of autophagic vesicles and Beclin1 resulting in an increase in 
the cardiotoxicity induced by doxorubicin.  Kobayashi also analyzed cell death when 
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doxorubicin was administered with rapamycin (stimulator of autophagy) and 3MA 
(autophagy inhibitor). Rapamycin in conjunction with doxorubicin caused an 
increase in cell death while 3MA was protective. Finally, another study (Smuder, 
Kavazis et al. 2013)performed in rat hearts reported that doxorubicin administration 
stimulated the LC3 flux and enhanced the expression of several autophagy related 
genes (Atg12, Atg12-5, Atg7, Atg4). 
 
Currently, the only hypothesis to explain the conflicting data with respect to 
the effect of doxorubicin on cardiac autophagy is inter-species differences, i.e. 
doxorubicin blocks and over stimulates autophagy in mice and rats respectively 
(Dirks-Naylor, 2013).  Overall, results obtained in Parkin-deficient mice following 
treatment with doxorubicin have thus revealed a phenotype that is more complex 
than initially expected. Future studies are needed to provide more definite 
explanations. Importantly, strategies such as the use of cardiac-specific inducible 
Parkin knockout models should be used to try to limit the occurrence of 
developmental compensation such as upregulation of macro-autophagy (Dimitrakis, 
Romay-Ogando et al. 2012).  This would allow to more specifically test the role of 
mitophagy in the cardiac response to doxorubicin. In addition, a more direct 
investigation of mitophagy and macro-autophagy should be performed to directly 
confirm the impact of doxorubicin on these quality control mechani
     
 
4 CONCLUSIONS 
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In mammalian tissues, mitochondrial quality control mechanisms play an important 
role in mitochondrial health.  The objective of our study was to determine if Parkin-
dependent mitophagy was necessary in the maintenance of normal mitochondria and 
cardiac function in response to doxorubicin-induced cardiotoxicity.  In line with 
previous findings in our laboratory, at baseline, the absence of Parkin did not induce 
a cardiac phenotype, but was associated with several mitochondrial dysfunctions 
such as respiratory impairment, elevated production of ROS and greater 
susceptibility to calcium-induced PTP opening; advocating for the fact that at 
baseline, Parkin contributes the maintenance of normal mitochondrial function. 
Similarly, doxorubicin also induced multiple mitochondrial dysfunctions in wild type 
mice that preceded cardiac dysfunctions.  This suggests that mitochondrial 
dysfunctions might represent a pathological mechanism as opposed to a consequence 
of doxorubicin-induced cardiotoxicity. Finally, in contrast to our hypothesis, the 
absence of Parkin did not accentuate mitochondrial dysfunctions following treatment 
with doxorubicin and even seemed to have a certain protective effect.  Several factors 
could contribute to explain this peculiar observation.  First, it is possible that since 
our parkin-deficient mice are already negatively impacted at baseline level, the 
subsequent consequences of treatment with doxorubicin cannot be appropriately 
measured.  Second, the existence of compensatory mechanisms, particularly the 
constitutive activation of macro-autophagy in Parkin knockout mice could afford a 
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certain level of protection considering that in mice models, impaired autophagy is 
suggested to contribute to doxorubicin-induced cardiomyopathy. However, 
considering the existing debate on the role the response of cardiac autophagy to 
anthracyclins, further work is required to elucidate this question
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